The rising prevalence of chronic diseases coupled with increasing research activities for cell-based research is found to be the major factor driving the...
According to the Global Cancer Observatory, in Saudi Arabia there are 830 new kidney cancer cases were registered in 2018, furthermore, 249 people were d...
The U.S. Department of Health and Human Services plans to end the federal COVID-19 Public Health Emergency on May 11, but ensuring access to novel vac...
The FDA clearance opens the door to the world's largest medical device market. With the cost effectiveness and demonstrated ability of our cardiac monitori...
The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to th...
Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the q...
Agilent Technologies Inc. (NYSE: A) announced the latest addition to the Cary 3500 UV-Vis Series with the release of the Agilent Cary 3500 Flexible U...
The project will see the site’s footprint increase by 32,000 square feet (3,000 square meters) to add capacity for the storage and handling of clinic...
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the de...
he Phase 1, first-in-human, multicenter clinical study seeks to characterize the safety, potential efficacy and evaluate possible biomarkers of response to...
One promising approach involves delivering antiviral compounds vaginally, using inserts, gels, films, or intravaginal rings. This method is appealing becau...
Xylyx Bio, a regenerative medicine company developing breakthrough technologies for organ and tissue repair, today announced findings from an independent c...
Synapse Biomedical, Inc. announced today that the FDA has granted premarket approval (PMA) of the NeuRx® Diaphragm Pacing System (NeuRx DPS®) for u...
Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, ...
© 2025 Biopharma Boardroom. All Rights Reserved.
